Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$27.95
$0.55(10.50%)
At close: 4:00 PM EST
$27.95
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $29.51
Previous CloseN/A
Volume1.27M
Average Volume (3M)5.56M
Market Cap
$2.23B
Enterprise Value$514.84M
Total Cash (Recent Filing)$328.96M
Total Debt (Recent Filing)$4.48M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 02, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding78,659,920
10 Day Avg. Volume13,976,451
30 Day Avg. Volume5,560,930
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.02K
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$36.83Price Target Upside31.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe recent initiation of a Phase 3 trial for palazestrant in combination with ribociclib indicates Olema's advancement in breast cancer treatment.
Market OpportunityOlema's estimation of the 1L market in combination with a CDK4/6i at over ~$10B represents a significant commercial opportunity in oncology.
Partnership And CollaborationThe partnership with Pfizer represents the 2nd clinical trial agreement between Olema and Pfizer, expanding the pipeline of pala combo trials and signaling confidence in its differentiated efficacy profile.
Bears Say
Competitive DynamicsThe timing pushback for Roche's topline data from their trial to 2026 is noteworthy and suggests competitive dynamics in the field.
Financial StabilityOlema has a relatively high annualized cash burn rate, which may impact its financial stability.
Investor SentimentThere is a significant short interest percentage in Olema's stock, indicating skepticism from some investors.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $29.51 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $2.23B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 89 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 11, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.015.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.54.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 78,659,920 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -5.862%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.83 (31.77% Upside)
$36.83 (31.77% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 24.7%
Last 30 Days ▲ 24.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.84%
12-Months-Change
Fundamentals
Return on Equity
-59.22%
Trailing 12-Months
Asset Growth
53.13%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.
OLMA Stock 12 Month Forecast
Average Price Target
$36.83
▲(31.77% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---